Table 2.

Baseline and follow-up serum parameters

	Ref. range	D1	D5	D6 ICU 1	D7 ICU 2	D8	D9	D10	D11	D12	D13	D14	D15	D16	D17	D20	D26	D28	D30	D32
						ICU 3	ICU 4	ICU 5	ICU 6	ICU 7	ICU 8	ICU 9	ICU10	ICU11	ICU12
Plasma exchange						x	x		x	x	x	x	x
Eculizumab														x
Creatinine (umol/L)	44–80	88	119	168	315	357	185	151	140	131	130	135	104	154	193	204	183	179	178	170
LDH (U/L)	<250	1125	2046	2580	2844	1655	1455	1043	1527	844	565	560	565	439	546	693	607	729	762	714
Haptoglobin					<0.10				<0.10	0.1		<0.10				0.72	1.21	1.35	1.81	1.94
CK (U/L)	<170	108	101	703	450	165	144	131	85	60	56	45	56	47	40	47	23
Myoglobin (ug/L)	25–58	116	257	701	355	193	136	129	91	84	73	63	73	157	237	286
Troponin (ng/L)	<14	17	169	3933	4814	1848	1435	1391	1419	1158	1006	1102	1006	2224	2175	1655	871	718		484
NT-proBNP (ng/L)	<210	1908	12390	32280	44443	11791	11791	6695	6038	4535	5350	4863	5350	9714	10470		9400
Haemoglobin (g/L)	134–170	153	157	130	119	98	109	104	93	76	87	76	86	83	81	93	75	80	89	85
Platelets (G/L)	143–400	260	83	53	23	12	16	16	18	19	14	17	24	31	41	81	134	192	285	285
Schistocytes (%/BF)	0			0	12	10	12	12					12		7		3			1
Fibrinogen (mg/L)	1.5–4.0		1.1	1.1	1.9	1.6	1.5	1.5	1		1.2	1.4	1.4	1.4	1.7		2.7	3.2	4.3	5
D-dimers (mg/L)	<0.5		>20	>20	>20	>20	>20	7.05			10.13	8.05	5.15	3.34	2.34		1.78	1.93	1.38	0.88

Before and after treatments with therapeutic plasma exchange (Days 8–9 and Days 11–15) and Eculizumab (Day 16).

BF, bright field; CK, creatine kinase; D-dimer, fibrin degradation product; LDH, lactate dehydrogenase; NT-proBNP, N-terminal pro-brain natriuretic peptide.